Salarius Pharmaceuticals Reports Q3 2025 Financial Results, Net Loss Decreases

Salarius Pharmaceuticals, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $873,467, a decrease from the $972,121 loss recorded in the same period of 2024. For the nine months ending September 30, 2025, the company reported a net loss of $3,540,825, down from $4,111,844 in the prior year. The reduction in losses is attributed to a cost-saving plan implemented in 2023, which included significant reductions in operating personnel and expenses. Research and development expenses for the quarter were $61,826, compared to $137,234 in the previous year, while general and administrative expenses decreased to $833,304 from $869,237.

The company’s total assets increased to $6.1 million as of September 30, 2025, up from $3.0 million at the end of 2024. This growth was primarily driven by an increase in cash and cash equivalents, which rose to $4.8 million from $2.4 million. Salarius also reported total stockholders' equity of $4.2 million, a significant increase from $1.5 million at the end of the previous fiscal year. The company’s liabilities also increased, totaling $1.8 million, compared to $1.5 million at the end of 2024, largely due to higher accounts payable and accrued expenses.

A significant strategic development for Salarius was the completion of its merger with Decoy Therapeutics on November 12, 2025. This merger is expected to enhance Salarius' capabilities in developing peptide conjugate therapeutics, leveraging Decoy's proprietary technology platform. The merger resulted in Decoy becoming a wholly owned subsidiary of Salarius, and the company anticipates that this integration will lead to advancements in its clinical development programs. Following the merger, Salarius appointed new leadership, including Frederick E. Pierce as CEO and Barbara Hibner as Chief Scientific Officer.

In terms of operational metrics, Salarius has not yet generated revenue from product sales and continues to face challenges as a clinical-stage biopharmaceutical company. The company has an accumulated deficit of $85.5 million as of September 30, 2025, and it acknowledges substantial doubt regarding its ability to continue as a going concern without additional capital. Salarius plans to raise further funds through equity offerings and collaborations, but it cannot guarantee success in these efforts.

Looking ahead, Salarius expects to increase its research and development expenditures as it advances the clinical development of the assets acquired from Decoy. The company believes that its current cash resources will support operations through the first quarter of 2027, but it will need to secure additional funding to sustain its operations and development activities beyond that period. The company remains focused on its goal of developing innovative treatments for cancer and other serious medical conditions, while navigating the complexities of the biopharmaceutical landscape.